Physician profile
Matthew W Martinez
NPI 1770556243
$418,716.20
in general payments reported to CMS, 2019-2025
27 companies · $118K in 2025
The $118K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $150 · 2021: $14K · 2022: $41K · 2023: $107K · 2024: $139K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $262K · Consulting Fee: $54K · Travel and Lodging: $39K · Food and Beverage: $8,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $261,581.67 |
| Consulting Fee | $54,374.00 |
| Travel and Lodging | $39,222.86 |
| Food and Beverage | $8,234.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $411,607.25 | 2021-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $3,070.13 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Genzyme Corporation | $1,241.30 | 2021-2025 | |
| Pfizer INC. | $392.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $386.19 | 2019-2025 | |
| Amgen INC. | $325.35 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.31 | 2021-2025 | Jardiance |
| Celgene Corporation | $300.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $119.60 | 2023-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $117.30 | 2022-2023 | Onpattro |
| Medical Graphics Corporation | $95.28 | 2020 | |
| Novo Nordisk INC | $82.75 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $69.05 | 2023-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $66.54 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $64.13 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $61.02 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $51.64 | 2023-2024 | Xarelto |
| Baxter Healthcare | $51.01 | 2020-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Boston Scientific Corporation | $45.93 | 2019 | |
| Bardy Diagnostics, INC. | $43.82 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.57 | 2025 | |
| Bridgebio Pharma, INC. | $34.20 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $32.48 | 2022-2023 | Nexletol |
| Kestra Medical Technology Services, INC. | $25.27 | 2024 | Assure Wcd |
| Chiesi USA, INC. | $23.21 | 2025 | Elfabrio |
| Amicus Therapeutics, INC. | $22.77 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.